Skip to main content
. 2017 Apr 27;8(26):42761–42771. doi: 10.18632/oncotarget.17463

Figure 3.

Figure 3

Receiver operating characteristic curve analysis of biomarker panel composed of CA19-9, APOA4 and TIMP1 for pancreatitis versus pancreatic cancer (A) and early pancreatic cancer (B) in the validation phase.